Updated terms.

CORRECTION NOTICE FOR DECISION ON ACQUISITION OF SHARES AND INVESTMENT SECURITIES OF OTHER CORPORATION

Correction Date: 2026-09-18

1. Disclosure Document Subject to Correction Decision on Acquisition of Shares and Investment Securities of Other Corporation

2. Submission Date of Disclosure Document Subject to Correction 2026-07-02

3. Reason for Correction Change in payment date

4. Corrected Items Item: Scheduled Acquisition Date Before Correction: 2026-11-21 After Correction: 2027-04-10

Before Correction (Strategy): 2) Third-party allotted paid-in capital increase (428,572 shares): Payment date 2026-09-21 (₩3,000,004,000) 3) Third-party allotted paid-in capital increase (571,427 shares): Payment date 2026-11-20 (₩3,999,989,000)

After Correction (Strategy): 2) Third-party allotted paid-in capital increase (428,572 shares): Payment date 2026-12-18 (₩3,000,004,000) 3) Third-party allotted paid-in capital increase (571,427 shares): Payment date 2027-04-09 (₩3,999,989,000)

DECISION ON ACQUISITION OF SHARES AND INVESTMENT SECURITIES OF OTHER CORPORATION

1. Issuing Company Company Name (Nationality): GP C&R Co., Ltd. (Republic of Korea) Representative Director: Shin Dong-seung Capital (KRW): 5,163,453,500 Relationship with Company: - Total Issued Shares: 10,326,907 shares Principal Business: New drug research and development using biotechnology techniques Acquisition of new shares by third-party allotment within recent 6 months: No

2. Acquisition Details Number of Shares to Acquire: 1,428,571 shares Acquisition Amount (KRW): 9,999,997,000 Equity Capital (KRW): 95,184,341,639 Ratio to Equity Capital (%): 10.51 Large Enterprise Status: Not applicable

3. Shareholding and Ownership Ratio After Acquisition Number of Shares Held: 1,428,571 shares Ownership Ratio (%): 12.15

4. Acquisition Method Cash acquisition (third-party allotted paid-in capital increase)

5. Purpose of Acquisition Addition of new growth drivers through new business initiatives

6. Scheduled Acquisition Date 2027-04-10

7. Major Asset Transfer Report Submission Target Not applicable Total Assets at End of Recent Fiscal Year (KRW): - Acquisition Price/Total Assets (%): -

8. Reverse Listing Applicability Not applicable Plan for Third-party Allotted Capital Increase within 6 Months: Yes

9. Compliance with Reverse Listing Requirements of Issuing Company (Other Corporation) No

10. Board Resolution Date (Decision Date) 2026-07-02 Attendance of Outside Directors: Attended (1), Not Attended (0) Attendance of Auditor (Audit Committee): Attended

11. Fair Trade Commission Reporting Target Status Not applicable

12. Put Option Contract Execution Status No Contract Details: -

13. Other Matters for Reference in Investment Decision

The capital and total issued shares of the issuing company in Section 1 above are based on the date of disclosure submission.

The equity capital in Section 2 (Acquisition Details) above is based on the consolidated financial statements as of the end of 2025.

The scheduled acquisition date in Section 6 above is the day following the payment date of the last third-party allotted paid-in capital increase among the following share acquisition schedule: 1) Third-party allotted paid-in capital increase (428,572 shares): Payment date 2026-07-20 (₩3,000,004,000) 2) Third-party allotted paid-in capital increase (428,572 shares): Payment date 2026-12-18 (₩3,000,004,000) 3) Third-party allotted paid-in capital increase (571,427 shares): Payment date 2027-04-09 (₩3,999,989,000)

Upon completion of participation in this paid-in capital increase, the Company will become the largest contributor holding 12.15% of the shares of the issuing company (GP C&R Co., Ltd.).

The current year, prior year, and year before prior in [Summary Financial Situation of Issuing Company] below are prepared based on (consolidated) financial statements for 2025, 2024, and 2023, respectively. (2025 is prepared based on individual financial statements as there are no subsidiaries)

The financial information in [Matters Regarding the Counterparty] below is prepared based on individual financial statements as there are no subsidiaries in 2025.

[Summary Financial Situation of Issuing Company] (Unit: Million KRW)

Category | Current Year | Prior Year | Year Before Prior Total Assets | 4,099 | 8,633 | 16,083 Total Liabilities | 2,625 | 5,612 | 5,606 Total Capital | 1,474 | 3,021 | 10,477 Capital | 5,163 | 5,163 | 5,163 Revenue | 2,518 | 2,000 | 0 Net Income (Loss) for the Period | -1,499 | -8,910 | -8,645

[Matters Regarding the Counterparty]

1. Personal Information Basic Information Name (Corporate Name): GP C&R Co., Ltd. Nationality: Republic of Korea Address (Principal Place of Business) [up to eup/myeon/dong]: 38 Nakseongdae-ro, Gwanak-gu, Seoul (Bongcheon-dong) Date of Birth (Business Registration Number, etc.): 110111-5263019 Occupation (Business Description): New drug research and development using biotechnology techniques

Status of Largest Shareholder, Representative Director, and Chief Executive Officer and Financial Situation (when counterparty is a corporation)

Category | Name | Number of Shares | Ownership Ratio (%) Largest Shareholder | Lee Jeong-gyu | 1,143,537 | 11.07 Representative Director | Shin Dong-seung | 1,075,000 | 10.41

(Unit: Million KRW) Fiscal Year: 2025 Closing Date: December Total Assets: 4,099 Capital: 5,163 Total Liabilities: 2,625 Revenue: 2,518 Total Capital: 1,474 Net Income (Loss): -1,499 External Auditor: Daejoo Accounting Firm Business Suspension Status: No Audit Opinion: Appropriate Business Closure Status: No

2. Relationship between Company and Counterparty 1. Relationship between Company and Counterparty: - 2. Relationship between Company's Largest Shareholder/Officers and Counterparty: (no entries) 3. Transaction History for Recent 3 Years (excluding routine transactions)

Category | Transaction Details Current Year | Prior Year | Year Before Prior |